Nyxoah S.A. (EBR:NYXH)

Market Cap	264.99M
Revenue (ttm)	4.52M
Net Income (ttm)	-59.24M
Shares Out	37.43M
EPS (ttm)	-1.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,794
Average Volume	72,657
Open	7.02
Previous Close	7.08
Day's Range	6.64 - 7.08
52-Week Range	6.26 - 12.20
Beta	0.61
RSI	28.56
Earnings Date	Mar 13, 2025

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2009
• Employees: 184
• Stock Exchange: Euronext Brussels
• Ticker Symbol: NYXH

Financial Performance

In 2024, Nyxoah's revenue was 4.52 million, an increase of 3.98% compared to the previous year's 4.35 million. Losses were -59.24 million, 37.1% more than in 2023.